Recent Updates
Recently added Catalysts
RADX Positive Sentiment Score: 75/100

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Tuesday, July 29, 2025 1 min read
Key Takeaway: Radiopharm Theranostics has announced that it has received Investigational New Drug (IND) approval from the US FDA. This approval enables the company to initiate a Phase I therapeutic clinical study targeting B7H3 with its drug Betabart (RV-01). This marks a significant step forward in their clinical development efforts.
Price reaction · baseline $5 (2025-07-29T16:20:00.000Z) · hit during market hours · 1 other RADX headline(s) in the window, move may be shared
day 0 close · peak
-3.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Radiopharm Theranostics has received IND approval from the FDA.
  • The approval allows the initiation of a Phase I therapeutic clinical study.
  • The study targets B7H3 with Betabart (RV-01), indicating progress in cancer treatment.

Full Press Release Details

• Announcements , Updates
• PDF
• July 29, 2025
Loading Viewer…

More Announcements & Updates

• Announcements
• October 29, 2024
• Announcements
• May 23, 2024
• Announcements
• February 28, 2023
• Announcements
• March 4, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What is the purpose of the Phase I study?

The Phase I study aims to target B7H3 using the drug Betabart (RV-01).

Who approved the IND for Radiopharm?

The IND was approved by the US FDA.

What is Betabart (RV-01)?

Betabart (RV-01) is a therapeutic drug developed by Radiopharm Theranostics.

When was the IND approval announced?

The IND approval was announced on July 29, 2025.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics B7H3 Betabart Phase I study FDA approval
Last updated: Jul 29, 2025